Abstract 1821: Preclinical efficacy and safety of CS5006, a novel integrin β4-targeting antibody-drug conjugate with a topoisomerase 1 inhibitor payload.
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institution: CStone Pharmaceuticals (China)
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7148834756
Cites:
Cited by:
Related to: